The European respiratory device market was valued at around $5.8 billion in 2018.
Major countries that contribute to the regional respiratory device market include UK, Germany, France, Italy, and Spain. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors that augmenting the growth of respiratory device market in Europe. The increasing demand from chronic obstructive pulmonary disease (COPD), Sleep Apnea and asthma patients in the major economies of the region is favoring the growth of the regional market.
The European respiratory device market is segmented on the basis of product and end-user. The respiratory product segment is further sub-segmented into therapeutic devices, diagnosis and monitoring devices, and consumables and accessories. The therapeutic devices segment is estimated to dominate the regional market and is also anticipated to grow at the fastest growth rate over the forecast period. The high cost of therapeutics device and significant demand for continuous positive airway pressure (CPAP) devices and masks, ventilator, oxygen concentrator, and oxygen hoods contribute majorly to the segmental growth of the market for therapeutic devices. Based on end-user, the market is analyzed into hospitals and clinics, and home care.
Additionally, the market is characterized by the presence of several players that are providing respiratory devices within and outside the region. Some of the key players of the market include ResMed Corp., Chiesi Farmaceutici S.P.A., GlaxoSmithKline PLC, 3M Co., Novartis AG, Teicos Pharma Ltd., and others.
The market players are adopting the strategy of merger & acquisition, product launch and expansion of their manufacturing facilities to increase their market share. For instance, in September 2017, Chiesi Farmaceutici completed the clinical study of Tribute with its Trimbow an extra-fine fixed-dose triple combination inhaler. The organization also got the marketing authorization for Trimbow from the European Commission. In November 2016, the company acquired Atopix therapeutics limited, the transaction aimed to develop novel treatments for asthma and strengthen the company's asthma portfolio.
The report covers:
- A comprehensive research methodology of the European respiratory device market.
- A detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European respiratory device market.
- Insights about market determinants which are stimulating the European respiratory device market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Key Topics Covered
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
5. Market Segmentation
5.1. European Respiratory Device Market by Product
5.1.1. Therapeutic Devices
5.1.2. Diagnostic and Monitoring Devices
5.1.3. Consumable and Accessories
5.2. European Respiratory Device Market by End-User
5.2.2. Hospitals and Clinics
6. Regional Analysis
6.6. Rest of Europe
7. Company Profiles
7.1. 3M Co.
7.2. Acorda Therapeutics, Inc.
7.3. Adamis Pharmaceuticals Corp.
7.4. Adherium Ltd.
7.5. Air Liquide S.A.
7.6. AstraZeneca PLC
7.8. Boehringer Ingelheim International GmbH
7.9. Chiesi Farmaceutici S.p.A.
7.10. Gilbert Technologies B.V.
7.11. GlaxoSmithKline PLC
7.12. H&T Presspart Manufacturing Ltd.
7.13. Hamilton Medical AG
7.14. Koninklijke Philips N.V.
7.15. Medtronic PLC
7.16. Novartis AG
7.17. PMD Device Solutions Ltd.
7.18. ResMed Corp.
7.19. Savara, Inc.
7.20. Teicos Pharma Ltd.
7.21. Teva Pharmaceuticals Industries Ltd.
7.22. Vitalograph Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/rksjza.